Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease. In addition, the company holds global rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase 3 clinical trial. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INNT
Previous Symbol
CUSIPN/A
Phone919-275-1933
Debt
Debt-to-Equity RatioN/A
Current Ratio1.04
Quick Ratio1.04
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.88 million
Price / Sales36.47
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.37) per share
Price / Book-1.92
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,920,000.00
Net MarginsN/A
Return on Equity-819.46%
Return on Assets-236.71%
Miscellaneous
Employees5
Outstanding Shares26,070,000
Market Cap$58.40 million
OptionableOptionable
Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions
What is Innovate Biopharmaceuticals' stock symbol?
Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."
How were Innovate Biopharmaceuticals' earnings last quarter?
Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.18. View Innovate Biopharmaceuticals' Earnings History.
When is Innovate Biopharmaceuticals' next earnings date?
What price target have analysts set for INNT?
2 Wall Street analysts have issued 1 year price targets for Innovate Biopharmaceuticals' shares. Their forecasts range from $35.00 to $35.00. On average, they expect Innovate Biopharmaceuticals' stock price to reach $35.00 in the next year. This suggests a possible upside of 1,230.8% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.
What is the consensus analysts' recommendation for Innovate Biopharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.
What are Wall Street analysts saying about Innovate Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Innovate Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Innovate Biopharmaceuticals, Inc. is a clinical stage biotechnology company. It focused on developing novel medicines for autoimmune/ inflammatory disease. The company's pipeline includes drug candidates for celiac disease, an unmet need, and ulcerative colitis. Its products includes INN-202 for the treatment of Celiac Disease with fast track designation, INN-108 for Inflammatory Bowel Disorders, mild to moderate Ulcerative Colitis and a GI orphan disease in a convenient liquid formulation, INN-329 for Magnetic Resonance Cholangiopancreatography which are in clinical stages. Innovate Biopharmaceuticals Inc., formerly known as Monster Digital, Inc., is based in SIMI VALLEY, United States. " (10/17/2018)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a composite discounted cash flow (DCF)-based analysis methodology, which ascribes $750M to INN-202 in celiac disease (70% probability of success based on positive Phase 2b data and 15% discount rate), $400M to INN-108 in ulcerative colitis (65% probability of success and 12% discount rate), and $130M to another formulation of larazotide, designated INN-217, for treatment of NASH (35% probability of success, along with a 15% discount rate)." (8/1/2018)
Has Innovate Biopharmaceuticals been receiving favorable news coverage?
News coverage about INNT stock has been trending neutral on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innovate Biopharmaceuticals earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totalling 696,715 shares, a decline of 35.8% from the October 31st total of 1,084,457 shares. Based on an average daily volume of 212,754 shares, the short-interest ratio is presently 3.3 days. Approximately 5.3% of the company's shares are short sold. View Innovate Biopharmaceuticals' Current Options Chain.
Who are some of Innovate Biopharmaceuticals' key competitors?
Some companies that are related to Innovate Biopharmaceuticals include CELYAD SA/ADR (CYAD), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK), ProMetic Life Sciences (PFSCF), Aduro BioTech (ADRO), Marinus Pharmaceuticals (MRNS), Axovant Sciences (AXON), Lannett (LCI), AcelRx Pharmaceuticals (ACRX), Urovant Sciences (UROV), Aquestive Therapeutics (AQST), Kamada (KMDA), Galectin Therapeutics (GALT), Synlogic (SYBX) and LifeVantage (LFVN).
Who are Innovate Biopharmaceuticals' key executives?
Innovate Biopharmaceuticals' management team includes the folowing people:
- Mr. Sandeep Laumas M.D., Exec. Chairman (Age 49)
- Dr. Christopher P. Prior, CEO & Director (Age 66)
- Mr. Jay P. Madan M.S., Pres, Chief Bus. Officer, Interim Principal Financial & Accounting Officer and Director (Age 53)
- Dr. June S. Almenoff, COO & Chief Medical Officer (Age 61)
- Jerry Gardner M.D., Head of Clinical Strategy
Who are Innovate Biopharmaceuticals' major shareholders?
Innovate Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.56%), Vanguard Group Inc. (1.24%), Jefferies Group LLC (0.38%), Dynasty Wealth Management LLC (0.14%), TIAA CREF Investment Management LLC (0.10%) and First Quadrant L P CA (0.09%). Company insiders that own Innovate Biopharmaceuticals stock include Christopher P Prior, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Institutional Ownership Trends for Innovate Biopharmaceuticals.
Which institutional investors are selling Innovate Biopharmaceuticals stock?
Which institutional investors are buying Innovate Biopharmaceuticals stock?
INNT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Jefferies Group LLC, First Quadrant L P CA, Russell Investments Group Ltd., Bank of Montreal Can, Hillview Capital Advisors LLC and Dynasty Wealth Management LLC. Company insiders that have bought Innovate Biopharmaceuticals stock in the last two years include Christopher P Prior, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Insider Buying and Selling for Innovate Biopharmaceuticals.
How do I buy shares of Innovate Biopharmaceuticals?
Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innovate Biopharmaceuticals' stock price today?
One share of INNT stock can currently be purchased for approximately $2.63.
How big of a company is Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals has a market capitalization of $58.40 million and generates $1.88 million in revenue each year. Innovate Biopharmaceuticals employs 5 workers across the globe.
What is Innovate Biopharmaceuticals' official website?
How can I contact Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]
MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
